Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Vyne prunes psoriasis trial, but keeps faith in BET inhibitor
Vyne has given up hope of resuming a psoriasis trial of its BET inhibitor under an FDA hold, but the biotech plans to persevere with the candidate.
James Waldron
Jul 2, 2025 10:33am
Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win
Jul 2, 2025 9:53am
Organon axes 'biggest potential opportunity' after trial fail
Jul 2, 2025 8:43am
Beckley Psytech psychedelic reduces depression symptoms in ph. 2
Jul 1, 2025 8:30am
Amgen, Zai say stomach cancer candidate hits phase 3 mark
Jun 30, 2025 10:36am
INmune flunks Alzheimer’s trial, focuses on subgroup efficacy
Jun 30, 2025 8:50am